|1.||Shumway, Stuart D: 6 articles (04/2015 - 05/2011)|
|2.||Hirai, Hiroshi: 5 articles (09/2011 - 01/2009)|
|3.||Mizuarai, Shinji: 4 articles (05/2011 - 01/2009)|
|4.||Edwards, Holly: 3 articles (01/2015 - 01/2014)|
|5.||Ge, Yubin: 3 articles (01/2015 - 01/2014)|
|6.||Taub, Jeffrey W: 3 articles (01/2015 - 01/2014)|
|7.||Altiok, Soner: 3 articles (01/2013 - 01/2012)|
|8.||Reed, Damon: 3 articles (01/2013 - 01/2012)|
|9.||Kreahling, Jenny M: 3 articles (01/2013 - 01/2012)|
|10.||Demuth, Tim: 3 articles (03/2012 - 05/2011)|
09/01/2011 - "MK-1775 also significantly enhanced the antitumor efficacy of radiation in vivo as shown in tumor growth delay studies, again for p53-defective tumors. "
01/01/2014 - "For example, combining p53 tumor expression data with mutational status could guide selection of tumors for therapeutic studies of agents where p53 status purportedly affects efficacy (e.g., MK-1775). "
04/15/2015 - "Consistent with limited drug delivery into orthotopic tumors, the normal brain to whole blood ratio following a single MK-1775 dose was 5%, and MALDI-MS imaging demonstrated heterogeneous and markedly lower MK-1775 distribution in orthotopic as compared with heterotopic GBM22 tumors. "
12/01/2012 - "The use of DBS coupled with liquid chromatography-tandem mass spectrometry analysis was evaluated for the quantification of MK-1775, a Wee-1 inhibitor under development as a chemo/radio-sensitizer for the treatment of cancer. "
01/01/2012 - "When dosed together, the combination of MK-8776 and MK-1775 induced more intense and more durable DNA damage as well as anti-tumor efficacy than either MK-8776 or MK-1775 dosed alone. "
|2.||Glioblastoma (Glioblastoma Multiforme)
12/01/2011 - "The purpose of this study was to determine the capacity of MK-1775, a potent Wee-1 inhibitor, to abrogate the radiation-induced G(2) checkpoint arrest and modulate radiosensitivity in glioblastoma cell models and normal human astrocytes. "
12/01/2011 - "These results show that MK-1775 can selectively enhance radiosensitivity in established glioblastoma cell lines. "
12/01/2011 - "MK-1775 abrogated the radiation-induced G(2) checkpoint and enhanced radiosensitivity in established glioblastoma cell lines in vitro and in vivo, without modulating radiation response in normal human astrocytes. "
12/01/2011 - "Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines."
04/15/2015 - "The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma."
|3.||Sarcoma (Soft Tissue Sarcoma)
01/01/2013 - "Our results together with the high safety profile of MK1775 strongly suggest that this drug can be used as a potential therapeutic agent in the treatment of both adult as well as pediatric sarcoma patients."
01/01/2013 - "Our data demonstrate that MK1775 treatment as a single agent at clinically relevant concentrations leads to unscheduled entry into mitosis and initiation of apoptotic cell death in all sarcomas tested. "
01/01/2012 - "Finally, in patient-derived sarcoma samples, we showed that MK1775 as a single agent causes significant apoptotic cell death, suggesting that Wee1 inhibition may represent a novel approach in the treatment of sarcomas."
01/01/2012 - "The cytotoxic effect of Wee1 inhibition on sarcoma cells seems to be independent of p53 status as all sarcoma cell lines with different p53 mutation were highly sensitive to MK1775 treatment. "
01/01/2012 - "Our data show that MK1775 treatment at clinically relevant concentrations leads to unscheduled entry into mitosis and initiation of apoptotic cell death in all sarcomas tested. "
|4.||Lung Neoplasms (Lung Cancer)
12/01/2015 - "Targeting of Carbon Ion-Induced G2 Checkpoint Activation in Lung Cancer Cells Using Wee-1 Inhibitor MK-1775."
09/01/2011 - "The in vivo efficacy of the combination of MK-1775 and radiation was assessed by tumor growth delay experiments using a human lung cancer cell line growing as a xenograft tumor in nude mice. "
|1.||DNA (Deoxyribonucleic Acid)
|10.||Biological Markers (Surrogate Marker)
|1.||Heterologous Transplantation (Xenotransplantation)